To study the evolution of multi-drug-resistant HIV-1 in treatment-experienced patients receiving foscarnet (PFA) as part of salvage therapy and to investigate the virological consequences of emerging mutations.
Methods
Genotypic and phenotypic resistance tests were performed on plasma viruses from seven patients at baseline and during treatment with PFA. The phenotypic effects of mutations suspected to be associated with PFA resistance were evaluated by site-directed mutagenesis of wild-type or thymidine analogue mutations (TAM)-carrying pNL4–3. Reversion of single mutations was performed in a patient-derived recombinant clone.
Results
Baseline multi-drug-resistant isolates exhibited hypersusceptibility to PFA. In two patients who received >12 months of PFA treatment, a novel mutation pattern including K70G, V75T, K219R and L228R emerged. These viruses had 3–6-fold resistance to PFA, a 2–20-fold decrease in resistance to zidovudine compared to baseline, and 14–39-fold resistance to lamivudine, in the absence of M184V. In wild-type clones mutations K70G and V75T induced moderate PFA resistance. In the case of TAMs, combinations of ≥3 mutations (K70G+K219R+L228R±V75T) induced PFA resistance and decreased zidovudine resistance 3–13-fold. These mutants exhibited high-level lamivudine resistance (>20-fold) without mutation M184V. Reversion of K70G→R and K219R→E in a patient-derived clone confirmed the contribution of individual mutations and the negative association between PFA resistance and zidovudine resistance.
Conclusions
In the context of multiple TAMs, hypersusceptibility to PFA was observed and a novel pattern of resistance, including alternative amino acid substitutions at TAM loci, emerged. This mutational pattern was associated with decreases in zidovudine resistance and surprisingly high-level lamivudine resistance.
References
1.
BalfourH.H.Jr., FletcherC.V., EriceA.Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS.Antimicrob Agents Chemother1996; 40: 2721–2726.
2.
GaubJ., PedersenC., PoulsenA.G.The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients.AIDS1987; 1: 27–33.
CanestriA., GhosnJ., WirdenM.Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance.Antivir Ther2006; 11: 561–566.
5.
MathiesenS., RogeB.T., WeisN., LundgrenJ.D., ObelN., GerstoftJ.Foscarnet used in salvage therapy of HIV-1 patients harbouring multiple nucleotide excision mutations.AIDS2004; 18: 1076–1078.
6.
MellorsJ.W., BazmiH.Z., SchinaziR.F.Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates.Antimicrob Agents Chemother1995; 39: 1087–1092.
7.
TachedjianG., HookerD.J., GurusingheA.D.Characterisation of foscarnet-resistant strains of human immunodeficiency virus type 1.Virology1995; 212: 58–68.
8.
TachedjianG., MellorsJ., BazmiH., BirchC., MillsJ.Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet.J Virol1996; 70: 7171–7181.
9.
HammondJ.L., KoontzD.L., BazmiH.Z.Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance.Antimicrob Agents Chemother2001; 45: 1621–1628.
10.
MeyerP.R., MatsuuraS.E., ZonarichD.Relationship between 3’-azido-3’-deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase.J Virol2003; 77: 6127–6137.
11.
RaceE., DamE., ObryV., PaulousS., ClavelF.Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies.AIDS1999; 13: 2061–2068.
12.
BouchonnetF., DamE., MammanoF.Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues.J Virol2005; 79: 812–822.
13.
RheeS.Y., FesselW.J., ZolopaA.R.HIV-1 protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance.J Infect Dis2005; 192: 456–465.
14.
KuritzkesD.R., BassettR.L., HazelwoodJ.D.Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens.J Acquir Immune Defic Syndr2004; 36: 600–603.
15.
GonzalesM.J., MachekanoR.N., ShaferR.W.Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population.J Infect Dis2001; 184: 998–1006.
EshlemanS.H., KrogstadP., JacksonJ.B.Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).J Infect Dis2001; 183: 1732–1738.
18.
AlbrechtM.A., BoschR.J., HammerS.M.Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.N Engl J Med2001; 345: 398–407.
19.
AlbertJ., WahlbergJ., LundebergJ.Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera.J Virol1992; 66: 5627–5630.
20.
HammerS.M., SquiresK.E., HughesM.D.A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.N Engl J Med1997; 337: 725–733.
21.
RuizL., RomeuJ., Martinez-PicadoJ.Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC.AIDS1996; 10: F61–F66.
22.
ShaferR.W., IversenA.K., WintersM.A., AguinigaE., KatzensteinD.A., MeriganT.C.Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team.J Infect Dis1995; 172: 70–78.
23.
TachedjianG., FrenchM., MillsJ.Coresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase.Antimicrob Agents Chemother1998; 42: 3038–3043.
24.
ArionD., KaushikN., McCormickS., BorkowG., ParniakM.A.Phenotypic mechanism of HIV-1 resistance to 3’-azido-3’-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase.Biochemistry1998; 37: 15908–15917.
25.
BoyerP.L., SarafianosS.G., ArnoldE., HughesS.H.Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase.J Virol2001; 75: 4832–4842.
26.
MeyerP.R., MatsuuraS.E., SoA.G., ScottW.A.Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism.Proc Natl Acad Sci U S A1998; 95: 13471–13476.
27.
MeyerP.R., MatsuuraS.E., TolunA.A.Effects of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type 1 reverse transcriptase.Antimicrob Agents Chemother2002; 46: 1540–1545.
28.
WhitcombJ.M., ParkinN.T., ChappeyC., HellmannN.S., PetropoulosC.J.Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.J Infect Dis2003; 188: 992–1000.
29.
MeyerP.R., MatsuuraS.E., MianA.M., SoA.G., ScottW.A.A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase.Mol Cell1999; 4: 35–43.
30.
HuangH., ChopraR., VerdineG.L., HarrisonS.C.Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance.Science1998; 282: 1669–1675.
31.
SarafianosS.G., DasK., DingJ., BoyerP.L., HughesS.H., ArnoldE.Touching the heart of HIV-1 drug resistance: the fingers close down on the dNTP at the polymerase active site.Chem Biol1999; 6: R137–R146.
32.
BoucherC.A., CammackN., SchipperP.High-level resistance to (-) enantiomeric 2’-deoxy-3’-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase.Antimicrob Agents Chemother1993; 37: 2231–2234.
33.
DescampsD., FlandreP., CalvezV.Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team).J Am Med Assoc2000; 283: 205–211.
34.
HavlirD.V., HellmannN.S., PetropoulosC.J.Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens.J Am Med Assoc2000; 283: 229–34.
35.
SchuurmanR., NijhuisM., van LeeuwenR.Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).J Infect Dis1995; 171: 1411–1419.
36.
SarafianosS.G., DasK., ClarkA.D.Jr.Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids.Proc Natl Acad Sci U S A1999; 96: 10027–10032.
37.
RomanoL., VenturiG., BloorS.Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118.J Infect Dis2002; 185: 898–904.
